Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Coya Therapeutics (COYA) over the last 4 years, with Q3 2025 value amounting to $1.1 million.

  • Coya Therapeutics' Share-based Compensation rose 3817.85% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 8840.63%. This contributed to the annual value of $2.7 million for FY2024, which is 20536.49% up from last year.
  • Latest data reveals that Coya Therapeutics reported Share-based Compensation of $1.1 million as of Q3 2025, which was up 3817.85% from $1.0 million recorded in Q2 2025.
  • Coya Therapeutics' 5-year Share-based Compensation high stood at $1.1 million for Q1 2025, and its period low was $21425.0 during Q1 2022.
  • In the last 4 years, Coya Therapeutics' Share-based Compensation had a median value of $262752.0 in 2023 and averaged $461988.0.
  • As far as peak fluctuations go, Coya Therapeutics' Share-based Compensation skyrocketed by 74194.63% in 2023, and later skyrocketed by 3817.85% in 2025.
  • Quarter analysis of 4 years shows Coya Therapeutics' Share-based Compensation stood at $71429.0 in 2022, then soared by 233.2% to $237999.0 in 2023, then skyrocketed by 232.16% to $790549.0 in 2024, then skyrocketed by 35.46% to $1.1 million in 2025.
  • Its Share-based Compensation was $1.1 million in Q3 2025, compared to $1.0 million in Q2 2025 and $1.1 million in Q1 2025.